Fibrogen Inc 8-K Filing
Ticker: KYNB · Form: 8-K · Filed: Jun 26, 2024 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2024 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Fibrogen Inc (ticker: KYNB) to the SEC on Jun 26, 2024.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se).
How long is this filing?
Fibrogen Inc's 8-K filing is 2 pages with approximately 450 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-06-26 08:00:18
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
Filing Documents
- fgen-20240626.htm (8-K) — 42KB
- fgen-ex99_1.htm (EX-99.1) — 39KB
- fgen-ex99_1s1.jpg (GRAPHIC) — 231KB
- fgen-ex99_1s2.jpg (GRAPHIC) — 503KB
- fgen-ex99_1s3.jpg (GRAPHIC) — 510KB
- fgen-ex99_1s4.jpg (GRAPHIC) — 288KB
- fgen-ex99_1s5.jpg (GRAPHIC) — 119KB
- fgen-ex99_1s6.jpg (GRAPHIC) — 399KB
- fgen-ex99_1s7.jpg (GRAPHIC) — 280KB
- fgen-ex99_1s8.jpg (GRAPHIC) — 383KB
- fgen-ex99_1s9.jpg (GRAPHIC) — 113KB
- fgen-ex99_1s10.jpg (GRAPHIC) — 240KB
- fgen-ex99_1s11.jpg (GRAPHIC) — 308KB
- fgen-ex99_1s12.jpg (GRAPHIC) — 316KB
- fgen-ex99_1s13.jpg (GRAPHIC) — 261KB
- fgen-ex99_1s14.jpg (GRAPHIC) — 376KB
- fgen-ex99_1s15.jpg (GRAPHIC) — 158KB
- fgen-ex99_1s16.jpg (GRAPHIC) — 401KB
- fgen-ex99_1s17.jpg (GRAPHIC) — 141KB
- fgen-ex99_1s18.jpg (GRAPHIC) — 217KB
- fgen-ex99_1s19.jpg (GRAPHIC) — 367KB
- fgen-ex99_1s20.jpg (GRAPHIC) — 305KB
- fgen-ex99_1s21.jpg (GRAPHIC) — 393KB
- fgen-ex99_1s22.jpg (GRAPHIC) — 281KB
- fgen-ex99_1s23.jpg (GRAPHIC) — 606KB
- fgen-ex99_1s24.jpg (GRAPHIC) — 263KB
- fgen-ex99_1s25.jpg (GRAPHIC) — 298KB
- fgen-ex99_1s26.jpg (GRAPHIC) — 280KB
- fgen-ex99_1s27.jpg (GRAPHIC) — 268KB
- fgen-ex99_1s28.jpg (GRAPHIC) — 280KB
- fgen-ex99_1s29.jpg (GRAPHIC) — 285KB
- fgen-ex99_1s30.jpg (GRAPHIC) — 265KB
- fgen-ex99_1s31.jpg (GRAPHIC) — 395KB
- fgen-ex99_1s32.jpg (GRAPHIC) — 311KB
- fgen-ex99_1s33.jpg (GRAPHIC) — 220KB
- fgen-ex99_1s34.jpg (GRAPHIC) — 284KB
- fgen-ex99_1s35.jpg (GRAPHIC) — 256KB
- fgen-ex99_1s36.jpg (GRAPHIC) — 399KB
- fgen-ex99_1s37.jpg (GRAPHIC) — 332KB
- fgen-ex99_1s38.jpg (GRAPHIC) — 175KB
- fgen-ex99_1s39.jpg (GRAPHIC) — 443KB
- fgen-ex99_1s40.jpg (GRAPHIC) — 328KB
- fgen-ex99_1s41.jpg (GRAPHIC) — 388KB
- fgen-ex99_1s42.jpg (GRAPHIC) — 389KB
- fgen-ex99_1s43.jpg (GRAPHIC) — 270KB
- fgen-ex99_1s44.jpg (GRAPHIC) — 125KB
- fgen-ex99_1s45.jpg (GRAPHIC) — 119KB
- 0000950170-24-077616.txt ( ) — 18883KB
- fgen-20240626.xsd (EX-101.SCH) — 23KB
- fgen-20240626_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On June 26, 2024, FibroGen, Inc. ("FibroGen") and Rahul Aggarwal, M.D., of University of California, San Francisco, gave an investor presentation discussing the unmet need and evolving treatment landscape for prostate cancer and the clinical development program for FG-3246. A copy of such investor presentation is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation titled "Virtual KOL Investor Event Series Part II: Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Center" dated June 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIBROGEN, INC. Date: June 26, 2024 By: /s/ Michael Lowenstein Michael Lowenstein Chief Legal Officer